Elevance Health, Inc. reported first-quarter 2026 revenues of $49.5 billion and adjusted EPS of $12.58, surpassing market expectations by 16.4%. In a positive shift, the company increased its full-year adjusted EPS guidance to at least $26.75 while initiating a $1.1 billion stock repurchase program. However, Elevance continues to face challenges with Medicaid margins, projecting a negative 1.75% operating margin outlook for the year, and is currently addressing compliance issues with a $935 million accrual linked to CMS risk adjustments.
“Elevance Health Reports First Quarter 2026 Results; Raises Full-Year Guidance.”
“Sassi Brian A - President & CEO Cons, EVP of Elevance Health, Inc. (WLP)”
“insiders · secured · position in Elevance Health, Inc. shares · larger”
“Elevance Health (ELV) · has a market cap of · 75.2 billion”
“Elevance Health, Inc. · is one of the most undervalued stocks · list of the 9 Most Undervalued Healthcare Stocks to Buy Now · true”
“Jefferies analyst David Windley · revised his outlook on ELV · price target · $391 from $395”
“Jefferies analyst David Windley · maintained a rating on ELV · Buy · true”
“Elevance Health, Inc. · announced a set of senior leadership changes · its Health Benefits segment and Carelon services division · true”
“Elevance Health, Inc. · provides managed care and health solutions to · over 119 million people · true”
“Elevance Health · reported first-quarter 2026 results · $49.5 billion · consolidated operating revenues”
“Elevance Health · experienced a · 40-basis-point increase · in its benefit expense ratio to 86.8%”
“Elevance Health · reported · first-quarter 2026 adjusted EPS · $12.58”
